Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Issuing More Shares: Good or Bad? – Buckeye Partners, L.P. (BPL), Citigroup Inc. (C) and More

Page 1 of 2

Buckeye Partners, L.P. (NYSE:BPL) recently announced plans to issue additional limited partnership units. Citigroup Inc. (NYSE:C) issued preferred shares to the government in 2008 during the financial meltdown. Simon Property Group, Inc (NYSE:SPG) issued shares in early 2012 and again in late 2012. How can you tell if these corporate actions are good or bad for shareholders?

Same Pie, More Slices

When a company issues shares of stock, it is, basically, selling ownership in the company and, thus, a right to the earnings of the company. It’s a pretty basic concept that underpins modern finance. In simple terms, a company is taking its earnings pie and cutting slices to give to shareholders. Eight shareholders, eight slices. Eight million shareholders, eight million slices.

Buckeye Partners, L.P. (NYSE:BPL)

With a secondary offering, however, the pie is the same size, but there are more slices being made. So if earnings are $100 and there are 10 shares, each shareholder is entitled to $10 of earnings. If the company doubles its share count to 20, then that same $100 pie is now cut into 20 slices, leaving shareholders with $5 each. That doesn’t sound like a good thing at all.

It All Depends

The answer is that it depends on why the shares are being issued. In most situations, the company receives cash from a stock issuance. The question to ask is what’s that money going to be used for?

For example Citigroup’s sale of preferred shares to the U.S. government was, essentially, an effort to ensure the company’s solvency. On one level that’s great, but the cost was quite high. After several machinations, the government wound up converting the preferred shares into common stock and was then a major company shareholder. When it sold its shares to the public, all that happened was the pie got cut into more slices. Investors probably would have been better off just moving on from Citi than sitting tight.

In early 2012, Amicus Therapeutics, Inc. (NASDAQ:FOLD) sold $62 million worth of stock to help fund its research efforts. That seems like a good thing, but, in late 2012 Amigal, a drug being developed with GlaxoSmithKline plc (ADR) (NYSE:GSK), performed poorly in a phase III trial. The shares fell almost 50%.

Although issuing shares to fund research is normal for biotech firms, those new shares are simply more claims on potential future earnings (most biotechs suffer through years of losses while trying to bring new drugs to market). If Amigal, or the company’s other drugs, don’t make it to market, investors are only getting hurt by additional share sales. Biotech is a high stakes investment world, so new share issues aren’t looked on as bad, but they should be something investors think about in relation to a company’s drug pipeline and the drug approval process.

The Business Model

Real estate investment trusts (REITs) are another area in which new shares are frequently issued. For example, in early 2012 Simon Property Group, Inc (NYSE:SPG) issued shares to help pay for a pair of acquisitions. In the normal course of business, REITs use credit facilities to pay for purchases and, once the acquisition closes, issue shares to raise cash to pay down the credit facility.

That’s a good thing, since the company is growing the business. It also forces these companies to get the market’s approval every time it buys something. A poor market reception to a stock issuance can be a sign that the market isn’t pleased. However, not all stock sales benefit a company.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!